|Bid||120.00 x 300|
|Ask||132.95 x 600|
|Day's Range||126.40 - 132.24|
|52 Week Range||35.98 - 147.63|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Alnylam Pharmaceuticals, Inc. a score of 21. Our analysis is based on comparing Alnylam Pharmaceuticals, Inc. with the following peers – Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Medicines Company, Sarepta Therapeutics, Inc., OPKO Health, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Sanofi Sponsored ADR, ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alnylam Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.
Before the approval of Alnylam's first drug, CEO John Maraganore backed the idea of raising prices pegged to inflation.
Chief Executive John Maraganore makes a pledge: “We will not arbitrarily increase prices beyond the price of inflation. We think the most difficult practice to explain to payors and patients is drug price increases. And we will not do that.”
CEO of Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) John Maraganore sold 73,415 shares of ALNY on 11/22/2017 at an average price of $130.9 a share.
Alnylam (ALNY) announced that the FDA has granted Breakthrough Therapy Designation for RNAi therapeutic candidate, patisiran.
Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.
Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.
The time is drawing near: our sixth annual Forbes Healthcare Summit will be held on Nov. 29 and Nov. 30. The event will take attendees through the whole spectrum of the healthcare business, from the cutting edge of gene therapy and to the hard economic choices every health system must make.
Categories: Yahoo FinanceGet free summary analysis Alnylam Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Alnylam Pharmaceuticals, Inc. – Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Medicines Company, Sarepta Therapeutics, Inc., OPKO Health, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Novartis AG Sponsored ADR ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Alnylam Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ALNY-US. Comparing the performance and risk of Alnylam Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
IN THE NEWS In one of the most tumultuous years in athleticwear in recent memory, adidas AG (ADR) (OTC: ADDYY ) has emerged as an industry leader: Link Following Intel and Advanced Micro Devices , it's ...
With a market capitalization of USD $12.14B, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) is a large-cap stock, which is considered by most investors as a safe bet. Common characteristics for these stocksRead More...
CNBC's Meg Tirrell speaks with John Maraganore, Alnylam CEO, about pricing for his company's new drug and his thoughts on Amazon's potential break into the biopharma industry.